Efficacy-Based Budget Impact Analysis of Secukinumab Vs Adalimumab in the Treatment of Ankylosing Spondylitis in Finland
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.737
https://www.valueinhealthjournal.com/article/S1098-3015(17)31071-9/fulltext
Title :
Efficacy-Based Budget Impact Analysis of Secukinumab Vs Adalimumab in the Treatment of Ankylosing Spondylitis in Finland
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31071-9&doi=10.1016/j.jval.2017.08.737
First page :
A528
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
701